Cargando…
Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton’s Tyrosine Kinase
Lupus nephritis (LN) is a potentially dangerous end organ pathology that affects upwards of 60% of lupus patients. Bruton’s tyrosine kinase (BTK) is important for B cell development, Fc receptor signaling, and macrophage polarization. In this study, we investigated the effects of a novel, highly sel...
Autores principales: | Chalmers, Samantha A., Doerner, Jessica, Bosanac, Todd, Khalil, Sara, Smith, Dustin, Harcken, Christian, Dimock, Janice, Der, Evan, Herlitz, Leal, Webb, Deborah, Seccareccia, Elise, Feng, Di, Fine, Jay S., Ramanujam, Meera, Klein, Elliott, Putterman, Chaim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872164/ https://www.ncbi.nlm.nih.gov/pubmed/27192942 http://dx.doi.org/10.1038/srep26164 |
Ejemplares similares
-
Highly selective inhibition of Bruton’s tyrosine kinase attenuates skin and brain disease in murine lupus
por: Chalmers, Samantha A., et al.
Publicado: (2018) -
Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014) -
Neuropsychiatric systemic lupus erythematosus persists despite attenuation of systemic disease in MRL/lpr mice
por: Stock, Ariel D., et al.
Publicado: (2015) -
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers
por: Litzenburger, Tobias, et al.
Publicado: (2020) -
Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)